Systematic drug screening reveals specific vulnerabilities and co-resistance patterns in endocrine-resistant breast cancer

BACKGROUND: The estrogen receptor (ER) inhibitor tamoxifen reduces breast cancer mortality by 31 % and has served as the standard treatment for ER-positive breast cancers for decades. However, 50 % of advanced ER-positive cancers display de novo resistance to tamoxifen, and acquired resistance evolv...

Descripción completa

Detalles Bibliográficos
Autores principales: Kangaspeska, Sara, Hultsch, Susanne, Jaiswal, Alok, Edgren, Henrik, Mpindi, John-Patrick, Eldfors, Samuli, Brück, Oscar, Aittokallio, Tero, Kallioniemi, Olli
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4932681/
https://www.ncbi.nlm.nih.gov/pubmed/27378269
http://dx.doi.org/10.1186/s12885-016-2452-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4932681/
https://www.ncbi.nlm.nih.gov/pubmed/27378269
http://dx.doi.org/10.1186/s12885-016-2452-5

Ejemplares similares